Achieve Life Sciences Inc
Open
5.56 0.54
Overzicht
Wijziging aandelenprijs
24u
Min
5.51
Max
5.73
Inkomsten | 4.5M -10M |
|---|---|
EPS | -0.19 |
Werknemers | 28 |
EBITDA | 4.3M -10M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +139.13% upside |
Volgende Winsten | 6 aug 2026 |
|---|
Marktkapitalisatie | -1M 573M |
|---|---|
Vorige openingsprijs | 5.02 |
Vorige sluitingsprijs | 5.56 |
Achieve Life Sciences Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
